
Immune sabotage: How a Vitamin A byproduct compromises the body’s normal anti-cancer response
Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A—all-trans retinoic acid—compromises both the body’s normal anti-cancer immune response and, in a different context, the efficacy of a promising type of cancer vaccine.








